2017
Outcomes from Autologous Hematopoietic Cell Transplantation versus Chemotherapy Alone for the Management of Light Chain Amyloidosis
Oke O, Sethi T, Goodman S, Phillips S, Decker I, Rubinstein S, Concepcion B, Horst S, Jagasia M, Kassim A, Harrell SL, Langone A, Lenihan D, Rawling KT, Slosky D, Cornell RF. Outcomes from Autologous Hematopoietic Cell Transplantation versus Chemotherapy Alone for the Management of Light Chain Amyloidosis. Transplantation And Cellular Therapy 2017, 23: 1473-1477. PMID: 28546074, DOI: 10.1016/j.bbmt.2017.05.020.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsBortezomibFemaleHematopoietic Stem Cell TransplantationHumansImmunoglobulin Light-chain AmyloidosisInduction ChemotherapyMaleMiddle AgedMultivariate AnalysisNatriuretic Peptide, BrainProportional Hazards ModelsProteinuriaRetrospective StudiesStroke VolumeTransplantation, AutologousTreatment OutcomeConceptsAutologous hematopoietic cell transplantationProgression-free survivalTransplantation-related mortalityHematopoietic cell transplantationOverall survivalCT cohortLight chain amyloidosisCell transplantationLower brain natriuretic peptide levelsChain amyloidosisBrain natriuretic peptide levelsMedian progression-free survivalSuperior progression-free survivalBortezomib-based treatmentExperienced transplantation centersGood partial responseNatriuretic peptide levelsCohort of patientsMajority of patientsHigher ejection fractionEligible patientsInduction chemotherapyInduction therapyPartial responseEjection fraction
2015
Interim Absolute Lymphocyte Count (ALC) As a Predictor of Survival in Hodgkin Lymphoma
Sethi T, Nguyen V, Morgan D, Greer J, Reddy N. Interim Absolute Lymphocyte Count (ALC) As a Predictor of Survival in Hodgkin Lymphoma. Blood 2015, 126: 2640. DOI: 10.1182/blood.v126.23.2640.2640.Peer-Reviewed Original ResearchProgression-free survivalAbsolute lymphocyte countClassical Hodgkin lymphomaNodular sclerosis Hodgkin lymphomaSuperior progression-free survivalOverall survivalHodgkin's lymphomaLymphocyte countAdvanced-stage Hodgkin lymphomaMixed cellularity Hodgkin's lymphomaCompletion of chemotherapyInitial chemotherapy treatmentMedian overall survivalAdvanced stage diseaseCompletion of therapyFirst-line chemotherapyStage Hodgkin lymphomaKaplan-Meier methodPredictors of survivalImmune effector cellsLog-rank testTime of apheresisNew therapeutic agentsTerms of histologyALC recovery